Approval · Notice of Compliance 33137 · 2024
RYDAPT: Notice of Compliance 33137
Issued April 29, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33137
- Date
- April 29, 2024
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of an alternate drug product manufacturer.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RYDAPT | Not yet assigned | — |
Medicinal ingredients
- MIDOSTAURIN 25 MG per CAP